EMEA-002961-PIP01-21-M01

Key facts

Invented name
Regkirona
Active substance
Regdanvimab
Therapeutic area
Vaccines
Decision number
P/0166/2022
PIP number
EMEA-002961-PIP01-21-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries
Celltrion Healthcare Hungary Kft.

Email: regulatory_eu@celltrion.com
Tel. +82 328505913

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
3 ratings
1 rating